grade
pharmaceutical primary standard
API family
methimazole
manufacturer/tradename
USP
mp
144-147 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CN1C=CNC1=S
InChI
1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
InChI key
PMRYVIKBURPHAH-UHFFFAOYSA-N
Gene Information
human ... TPO(7173)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Methimazole USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Methimazole Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 甲巯咪唑
flash_point_f
Not applicable
flash_point_c
Not applicable
target_organs
Endocrine system
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 1A - Skin Sens. 1 - STOT RE 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
M Clementi et al.
American journal of medical genetics, 83(1), 43-46 (1999-03-17)
We report on a further case of congenital anomalies in a child exposed to methimazole during the first trimester of pregnancy (from first to seventh gestational week), and define a specific malformation pattern related to prenatal methimazole exposure and consisting
Ashish A Vyas et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 16(4), 673-676 (2010-05-05)
To report a case of a patient with Graves disease presenting with agranulocytosis induced by methimazole, with subsequent thyroid storm and successful therapeutic use of plasmapheresis. The clinical features and laboratory findings in a patient with agranulocytosis and thyroid storm
Fernando Bolaños et al.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 54(4), 307-310 (2002-11-06)
Long-term thionamide treatment is considered one of the main resources for Graves' hyperthyroidism. Although a 54.2% remission rate in patients so treated in Mexico was previously reported, most articles have shown a wide variation over time. In the present article
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1411005-200MG | 04061833860526 |